Advertisement
Person › Details
Ericc Quéméneur (Transgene S.A. (Euronext: TNG))
Quéméneur, Eric (Mérieux 201410 EVP RnD at Transgene SA)
Organisation | Transgene S.A. (Euronext: TNG) | |
Group | Mérieux (Group) | |
Product | gene therapy | |
Product 2 | TG4010 (MVA-MUC1-IL2) (Transgene) | |
Record changed: 2020-05-07 |
Advertisement
More documents for Ericc Quéméneur
- [1] Transgene S.A.. (5/4/20). "Press Release: Vaxxel Acquires Transgene’s DuckCelt-T17 Cell Line to Develop Industrial-scale Vaccines against Respiratory Viruses". Lyon & Strasbourg....
- [2] Transgene S.A.. (10/2/17). "Press Release: Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors". Strasbourg & Belfast....
- [3] Transgene S.A.. (9/21/17). "Press Release: Transgene Launches Invir.IO, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses". Strasbourg....
- [4] Servier. (6/29/17). "Press Release: Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic CAR-T"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top